MediSpectra Inc. of Lexington, Mass., has received FDA approval for the Luma cervical imaging system. When used in conjunction with colposcopy — for women who have had abnormal Pap test results — the noncontact optical imaging device is expected to improve the detection of high-grade cervical cancer precursors. A 12-s scan combines fluorescence spectroscopy, white-light diffuse reflectance spectroscopy and video imaging to provide results during the examination.